R&D channel feed

Fresh off ALS drug with­draw­al, Amy­lyx touts in­ter­im rare dis­ease da­ta for the same ther­a­py

Last year

Lipocine’s weight loss drug shows ear­ly signs of keep­ing mus­cle mass in Ph2

Last year

Af­ter ap­provals for one of can­cer's 'un­drug­gable' tar­gets, re­search in­to new KRAS ther­a­pies booms: #AACR24

Last year
Pharma

Ear­ly can­cer vac­cine da­ta breathe new life in­to the field, but many ques­tions re­main: #AACR24

Last year

No­var­tis paus­es en­roll­ment for Kisqali breast can­cer tri­als to align with ni­trosamine guide­lines

Last year
Manufacturing

As­traZeneca's ‘ra­diosen­si­tiz­er’ may en­hance ef­fi­ca­cy of ra­di­a­tion for dead­ly brain can­cer: #AACR24

Last year

Ex­clu­sive: Sanofi to close Dutch NK cell ther­a­py biotech ac­quired in 2020

Last year
Pharma

Brain­Storm out­lines plans for what may be fi­nal at­tempt to bring ALS drug to mar­ket

Last year
FDA+

With Ph3 da­ta, Pfiz­er wants to have the ‘first and on­ly’ RSV vac­cine to cov­er adults as young as 18 years old

Last year

As­traZeneca eyes a safer PARP in­hibitor, with near­ly 50% re­sponse in ad­vanced breast can­cer pa­tients: #AACR24

Last year

No­vo fur­ther boosts ev­i­dence for semaglu­tide’s heart ben­e­fits be­yond weight loss: #ACC24

Last year

Al­ny­lam’s RNAi ther­a­py pass­es sec­ond Phase 2 hy­per­ten­sion test, with third un­der­way: #ACC24

Last year

Ar­row­head re­ports full Phase 2b da­ta for lipid drug, but Io­n­is is a step ahead: #ACC24

Last year

Io­n­is presents piv­otal rare dis­ease da­ta, builds to­ward first so­lo launch: #ACC24

Last year

Bris­tol My­ers touts long-term ef­fi­ca­cy of re­cent­ly ac­quired Karuna drug

Last year

As­traZeneca un­veils pos­i­tive Phase 3 da­ta to move Imfinzi in­to ear­li­er stages of lung can­cer

Last year
Pharma

‘Look be­fore you leap’: Cari­bou to start Ph1 au­toim­mune study of CAR-T ther­a­py

Last year
Cell/Gene Tx

No­var­tis plots new Plu­vic­to fil­ing time­line af­ter wait­ing for over­all sur­vival re­sults

Last year

eF­FEC­TOR's lead lung can­cer pro­gram falls through, stock crash­es

Last year

Cure­Vac re­leas­es mixed in­ter­im Phase 2 da­ta for sea­son­al flu vac­cine

Last year

Ex­clu­sive: Jim Wil­son start­up gets FDA green light for first test of gene edit­ing in ba­bies

Last year
Cell/Gene Tx

Aca­d­e­m­ic tri­al sug­gests mod­est GLP-1 ef­fect in Parkin­son's dis­ease, but ques­tions re­main

Last year

Mer­ck KGaA inks ADC dis­cov­ery deal with AI tech­bio worth up to $1.4B in mile­stones

Last year
Deals

LENZ plans NDA sub­mis­sion for pres­by­opia eye drops this year, looks to launch in 2025

Last year
First page Previous page 46474849505152 Next page Last page
A service from the Financial Times